BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 1549151)

  • 1. Thalidomide for the treatment of chronic graft-versus-host disease.
    Vogelsang GB; Farmer ER; Hess AD; Altamonte V; Beschorner WE; Jabs DA; Corio RL; Levin LS; Colvin OM; Wingard JR
    N Engl J Med; 1992 Apr; 326(16):1055-8. PubMed ID: 1549151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to thalidomide therapy in refractory chronic graft-versus-host disease.
    Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NK; Wagner J; Enright H
    Bone Marrow Transplant; 2000 Oct; 26(8):865-9. PubMed ID: 11081386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
    Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
    Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children.
    Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasciulli A; Vassallo E; Miniero R; Uderzo C
    Bone Marrow Transplant; 1998 Mar; 21(6):577-81. PubMed ID: 9543061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
    Chao NJ; Parker PM; Niland JC; Wong RM; Dagis A; Long GD; Nademanee AP; Negrin RS; Snyder DS; Hu WW; Gould KA; Tierney DK; Zwingenberger K; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1996 May; 2(2):86-92. PubMed ID: 9118303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation.
    Cole CH; Rogers PC; Pritchard S; Phillips G; Chan KW
    Bone Marrow Transplant; 1994 Dec; 14(6):937-42. PubMed ID: 7711671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide for treatment of graft-versus-host disease.
    Vogelsang GB; Hess AD; Santos GW
    Bone Marrow Transplant; 1988 Sep; 3(5):393-8. PubMed ID: 3056547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological features in patients with hepatic graft-versus-host disease.
    Chiba T; Yokosuka O; Goto S; Fukai K; Imazeki F; Kohno Y; Nishimura M; Saito Y; Saisho H
    Hepatogastroenterology; 2005; 52(66):1849-53. PubMed ID: 16334791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA).
    Vogelsang GB; Wolff D; Altomonte V; Farmer E; Morison WL; Corio R; Horn T
    Bone Marrow Transplant; 1996 Jun; 17(6):1061-7. PubMed ID: 8807115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensive chronic graft-versus-host disease of skin successfully treated with thalidomide.
    Nair V; Sharma A; Ghosh I; Arora S; Sahai K; Dutta V
    J Assoc Physicians India; 2005 Nov; 53():988-90. PubMed ID: 16515241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
    Teachey DT; Bickert B; Bunin N
    Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate.
    Wang Y; Xu LP; Liu DH; Chen H; Chen YH; Han W; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):505-11. PubMed ID: 19285639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group.
    Kanamaru A; Takemoto Y; Kakishita E; Dohy H; Kodera Y; Moriyama Y; Shibata A; Kasai M; Katoh S; Saitoh H
    Bone Marrow Transplant; 1995 Jun; 15(6):885-9. PubMed ID: 7581086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide back in good graces--seems to help GVHD patients.
    Oncology (Williston Park); 1988 Sep; 2(9):29. PubMed ID: 3275064
    [No Abstract]   [Full Text] [Related]  

  • 20. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
    Akpek G; Lee SM; Anders V; Vogelsang GB
    Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.